Jump to: navigation, search

Trizivir is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline:

It is indicated in the treatment of AIDS/HIV.

The combination of drugs is helpful in that it helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, only AZT has passed out of United States patent protection.